Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.22.2.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating expenses:        
Research and development $ 4,570,562 $ 805,392 $ 9,702,978 $ 1,779,285
General and administrative 1,483,573 1,265,486 5,154,324 1,964,978
Total operating expenses 6,054,135 2,070,878 14,857,302 3,744,263
Loss from operations (6,054,135) (2,070,878) (14,857,302) (3,744,263)
Other income (expense):        
Interest expense, net   140,912 282,064 276,317
Change in fair value of financial instruments 61,407 997,095 2,972,272 (3,526,590)
Gain on extinguishment of convertible debt and derivative liability     1,307,421  
Other income 35,853 4,052 62,915 1,673
Total other income (expense), net 97,260 860,235 4,060,544 (3,801,234)
Net loss (5,956,875) (1,210,643) (10,796,758) (7,545,497)
Other comprehensive gain/(loss):        
Gain/(loss) on foreign currency translation (131,874) 42,659 (82,397) (102,558)
Comprehensive loss $ (6,088,749) $ (1,167,984) $ (10,879,155) $ (7,648,055)
Net loss per Common Share, basic $ (0.85) $ (0.20) $ (1.51) $ (1.44)
Net loss per Common Share, diluted $ (0.85) $ (0.20) $ (1.51) $ (1.44)
Weighted-average Common Shares, basic 7,195,529 5,919,485 7,195,529 5,310,483
Weighted-average Common Shares, diluted 7,195,529 5,919,485 7,195,529 5,310,483